TP53 and ovarian carcinoma: Analyses of ovarian cancer cohorts in the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (https://www.ncbi.nlm.nih.gov/geo/) and the Genome Data Commons Data Portal (https://portal.gdc.cancer.gov/) [30] revealed that there is a significant correlation (p = 0.011) between the level of ABCB1 gene expression and PFS in patients with p53 mutation-harboring ovarian cancer previously treated with platinum drugs, displaying a median survival of 19.13 months for the low ABCB1 expression cohort and 15.87 months for the high ABCB1-expressing group (Fig. 7C).